High-risk patients who added evolocumab to standard cholesterol therapy had a lower risk of dying over five years, even without a prior heart attack or stroke.
The finding extends a proven heart-attack drug into a much larger group of patients.
The analysis covered 12,257 patients in the VESALIUS-CV trial, presented August 31 at the ESC Congress 2026 in Munich and published simultaneously in Circulation.
All-cause mortality at five years was 7.9 percent with evolocumab and 9.7 percent with placebo, a roughly 20 percent relative reduction.
Also read: Researchers find new link between sitting and cancer risk
Median follow-up was 4.6 years, and the survival gap began to open after about 1.5 years of treatment.
Evolocumab is a PCSK9 inhibitor sold by Amgen as Repatha. The injection blocks a protein that limits how much LDL, or "bad," cholesterol the liver can clear from the blood, and it lowered LDL by roughly 55 percent in the trial.
Until now, the clearest survival signal for the drug class had come from patients with established heart disease.
The new analysis suggests the benefit reaches people who are high-risk but have not yet had an event.
Also read: Going plant-based may protect your heart or raise your risk by 40%: one thing decides
What "high risk" mean
Enrollees had no prior heart attack or stroke, but carried a heavy risk load.
All had an LDL level of at least 90 mg/dL despite optimized lipid-lowering therapy.
They also had either atherosclerosis, meaning fatty plaque buildup in the arteries, or high-risk diabetes. Median age was 66, and 43 percent were women.
The mortality benefit held across age, sex, geography and starting LDL level.
Also read: 71% of women had this warning sign weeks before their heart attack
Cardiovascular and non-cardiovascular death rates fell to a similar degree.
What it means for treatment
The FDA had already expanded Repatha's label on August 25, 2025 to cover adults at increased risk of major cardiovascular events from uncontrolled LDL, removing the previous requirement that a patient must already have diagnosed heart disease.
Guidelines and insurance rules tend to lag such approvals, and PCSK9 inhibitors remain more expensive than generic statins.
People whose LDL stays elevated on statins can ask their doctor whether a PCSK9 inhibitor now fits their profile.
Also read: How strong should your grip be? The norms by age that predict your health
Also read: How eating sweet potatoes every day can affect your eyes, gut and heart
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.